Phase
Condition
Cancer
Cancer/tumors
Astrocytoma
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Part A
Inclusion Criteria:
18 years of age or over
Will receive or are currently receiving concurrent phase treatment with TMZ for highgrade glioma (WHO Grade 3 or Grade 4 Astrocytoma, Oligodendroglioma orGlioblastoma).
Provision of informed consent to participate.
Exclusion
Exclusion Criteria:
a. Patients who, in opinion of supervising clinician, are clinically too unwell to provide informed consent or for whom additional blood samples, or other research samples, would not be indicated or appropriate.
Part B
Inclusion Criteria:
18 years of age or over
Receiving or received treatment with TMZ for high grade glioma (WHO Grade 3 or Grade 4 Astrocytoma, Oligodendroglioma or Glioblastoma).
Developed any CTCAE Grade ≥3 Haematological Toxicity associated with Temozolomide,and/or any 1 of:
i. Platelet count <100 x 109/L ii. Neutrophil Count <1.0 x 109/L iii. Haemoglobin value <8.0 g/L iv. Omission of daily TMZ dose for ≥3 consecutive days during concurrent phase due to FBC concerns v. Deferral of subsequently due TMZ cycle by ≥7 days during adjuvant phase; vi. Dose reduction or permanent discontinuation of TMZ for reasons of haematological toxicity (as per treating physician discretion); vii. Use of growth factors, platelets or packed-cell transfusions during the course of TMZ.
d. Provision of informed consent to participate.
Exclusion criteria:
a. Patients who, in opinion of supervising clinician, are clinically too unwell to provide informed consent or for whom additional blood samples, or other research samples, would not be indicated or appropriate.
Study Design
Study Description
Connect with a study center
Cork University Hospital
Cork,
IrelandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.